Coenzyme Q10 for Parkinson's disease.

Area of Science:

• Neurology
• Nutritional Neuroscience
• Neurodegenerative Diseases

Background:

• Preclinical studies indicate coenzyme Q10 (CoQ10) protects the nigrostriatal dopaminergic system in Parkinson's disease models.
• Clinical trials have explored CoQ10's neuroprotective effects in early to midstage Parkinson's disease patients.

Purpose of the Study:

• To evaluate the efficacy and safety of coenzyme Q10 compared to placebo in Parkinson's disease patients.
• To assess randomized controlled trial (RCT) evidence for CoQ10's impact on disease progression and patient well-being.

Main Methods:

• Systematic search of major databases (Cochrane, MEDLINE, EMBASE) and conference proceedings.
• Inclusion of four randomized, double-blind, placebo-controlled trials involving 452 patients with early to midstage Parkinson's disease.
• Independent data extraction and quality assessment by two reviewers, with efforts to obtain missing information from study authors.

Main Results:

• Coenzyme Q10 (1200 mg/d for 16 months) demonstrated improvements in activities of daily living (ADL) UPDRS and Schwab and England scores.
• No significant differences were observed in withdrawals due to adverse effects between CoQ10 and placebo groups.
• Mild elevations in the risk of pharyngitis and diarrhea were noted but were not statistically significant.

Conclusions:

• Coenzyme Q10 therapy (1200 mg/d for 16 months) was well-tolerated in Parkinson's disease patients.
• Observed improvements in ADL UPDRS and Schwab and England scores warrant further confirmation with larger studies.
• The effects of coenzyme Q10 on other UPDRS subscores require additional investigation.